Investors

Home / Investors / Press Releases

Press Releases

18Sep

CymaBay Therapeutics to Present at Two Investor Conferences

11Sep

CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis

15Aug

CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology

10Aug

CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update

7Aug

CymaBay to Report Second Quarter 2017 Financial Results on Thursday, August 10

24Jul

CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

19Jul

CymaBay Announces Pricing of Public Offering of Common Stock

17Jul

CymaBay Announces Proposed Public Offering of Common Stock

17Jul

CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

26Jun

CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance

RSS
Show All

Contact Info

  • 7575 Gateway Blvd., Suite 110
    Newark, CA 94560
  • +1 (510) 293-8800
  • +1 (510) 293-9090

Quick Links

Pipeline